PROMISE Study Results: Time to Start Screening for Myeloma? | Irene Ghobrial, MD

PROMISE Study Results: Time to Start Screening for Myeloma? | Irene Ghobrial, MD
PROMISE Study Results: Time to Start Screening for Myeloma? | Irene Ghobrial, MD
The "No More MGUS" Project: Why It's Time to End "Undetermined" in MGUS | Bruno Paiva, PhD
The "No More MGUS" Project: Why It's Time to End "Undetermined" in MGUS | Bruno Paiva, PhD
What’s New for Newly Diagnosed Multiple Myeloma | Rahul Banerjee, MD, FACP
What’s New for Newly Diagnosed Multiple Myeloma | Rahul Banerjee, MD, FACP
ReKInDLE study: Iberdomide Quadruplet Shows Promising Results | Benjamin Diamond, MD
ReKInDLE study: Iberdomide Quadruplet Shows Promising Results | Benjamin Diamond, MD
IMMUNOPLANT-Will Linvoseltamab Consolidation Replace ASCT? | Dickran Kazandjian, MD
IMMUNOPLANT-Will Linvoseltamab Consolidation Replace ASCT? | Dickran Kazandjian, MD
IMerge Phase 3: Long-Term Results of Imetelstat in Lower-Risk MDS | Valeria Santini, MD
IMerge Phase 3: Long-Term Results of Imetelstat in Lower-Risk MDS | Valeria Santini, MD
Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD
Optimal 2nd-Line Treatment for CLL? GAIA/CLL13 Findings | Carsten Niemann, MD
Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD
Treating High Risk Smoldering Multiple Myeloma- Aquila Updates | Natalie Callander, MD
Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD
Your Voice Matters: The Power of Patient-Reported Outcomes in Myeloma | Fabio Efficace, PhD
Updates -Smoldering Multiple Myeloma from ASH 2025 | Rahul Banerjee, MD, FACP